RNTX Rein Therapeutics Inc revenue, earnings and financials

For the quarter ended June 30, 2026, Rein Therapeutics Inc reported revenue of $0, net income of −$6.38M and diluted EPS of −$0.10; over the last four quarters revenue was $0 and net income −$49.8M; for the fiscal year ended December 2025 revenue was $0.

RNTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$50.6M, net income −$49.9M (margin n/a), EPS −$1.96
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$65.1M, net income −$62.9M (margin n/a), EPS −$3.51
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$16.3M, net income −$15.7M (margin n/a), EPS −$3.42
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$27.6M, net income −$27.3M (margin n/a), EPS −$6.02
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$26.6M, net income −$26.2M (margin n/a), EPS −$5.89

RNTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0, net income −$6.38M, EPS −$0.10
• Quarter ended Mar 31, 2026: revenue $0, net income −$5.84M, EPS −$0.19
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$32.0M, EPS −$1.22
• Quarter ended Sep 30, 2025: revenue $0, net income −$5.58M, EPS −$0.21
• Quarter ended Jun 30, 2025: revenue $0, net income −$6.82M, EPS −$0.28
• Quarter ended Mar 31, 2025: revenue $0, net income −$5.50M, EPS −$0.25
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$41.0M, EPS −$1.93
• Quarter ended Sep 30, 2024: revenue $0, net income −$5.85M, EPS −$0.27
• Quarter ended Jun 30, 2024: revenue $0, net income −$8.94M, EPS −$0.45
• Quarter ended Mar 31, 2024: revenue $0, net income −$7.11M, EPS −$0.86
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$7.31M, EPS −$1.58
• Quarter ended Sep 30, 2023: revenue $0, net income −$1.83M, EPS −$0.40
• Quarter ended Jun 30, 2023: revenue $0, net income −$1.79M, EPS −$0.39
• Quarter ended Mar 31, 2023: revenue $0, net income −$4.78M, EPS −$1.05
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$4.55M, EPS −$1.00
• Quarter ended Sep 30, 2022: revenue $0, net income −$6.37M, EPS −$1.40
• Quarter ended Jun 30, 2022: revenue $0, net income −$7.99M, EPS −$1.76
• Quarter ended Mar 31, 2022: revenue $0, net income −$8.42M, EPS −$1.86
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$6.80M, EPS −$5.68
• Quarter ended Sep 30, 2021: revenue $0, net income −$6.70M, EPS −$0.07

RNTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$19.4M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow −$22.3M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$19.8M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$24.9M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2021: operating cash flow −$23.8M, share buybacks n/a, dividends $0.00 per share

RNTX balance sheet

• Jun 30, 2026: cash $8.54M, total assets $66.0M, total liabilities $10.8M, shareholders' equity $55.2M
• Mar 31, 2026: cash $4.45M, total assets $26.3M, total liabilities $14.7M, shareholders' equity $11.6M
• Dec 31, 2025: cash $3.22M, total assets $24.2M, total liabilities $7.24M, shareholders' equity $16.9M
• Sep 30, 2025: cash $4.05M, total assets $53.7M, total liabilities $7.52M, shareholders' equity $46.2M
• Jun 30, 2025: cash $5.72M, total assets $57.5M, total liabilities $9.47M, shareholders' equity $48.0M
• Mar 31, 2025: cash $7.43M, total assets $57.6M, total liabilities $7.75M, shareholders' equity $49.9M
• Dec 31, 2024: cash $12.9M, total assets $62.2M, total liabilities $7.80M, shareholders' equity $54.4M
• Sep 30, 2024: cash $17.7M, total assets $104M, total liabilities $8.99M, shareholders' equity $95.2M

What is RNTX's revenue?

Rein Therapeutics Inc reported $0 of revenue over its last four quarters, through June 30, 2026.

Is RNTX profitable?

No. Rein Therapeutics Inc lost $49.8M over the last four quarters.

What is RNTX's EPS?

Diluted earnings per share over the last four quarters were −$1.72; −$0.10 in the latest quarter.

RNTX ownership and insider trades · All stocks